Minerva Neurosciences returns to GAAP profit in Q2 FY26 at $17.47 million; GAAP net loss widens to $107.94 million in H1 FY26

• Minerva Neurosciences swung to GAAP net income of USD 17.5 million in Q2 2026 from a loss a year earlier, driven by a USD 27.6 million non-cash warrant revaluation gain.
• R&D expense more than doubled to USD 7.2 million, due to C19 trial costs and higher compensation; G&A expense rose 64.8% to USD 3.5 million.
• For the first half, GAAP net loss widened to USD 107.9 million from a smaller loss, reflecting a USD 81.8 million non-cash warrant revaluation loss.
• Cash, cash equivalents, marketable securities, and restricted cash fell to about USD 75.4 million at June 30 from USD 82.4 million at year-end 2025.
• The confirmatory Phase 3 C19 trial of roluperidone remains on track for topline efficacy data in 2H 2027, with Phase B topline data expected in 2H 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minerva Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608070700OMX_____CNEWS_EN_GNW9805770_en) on August 07, 2026, and is solely responsible for the information contained therein.